ANGPTL3

Biomarker1 paper1 finding

Interventions

1

Gene-editing

downin humans1

1 study

Gene-editing decreases ANGPTL3 in humans.
Reviewearly phase clinical evaluation
CRISPR therapy for dyslipidemia · Current opinion in lipidology · 18 Sep 2026

Gene-editing →

Latest

10

Annual Review of Pharmacology and ToxicologyReviewYesterday

Small Interfering RNA in Cardiovascular Disease: A New Frontier in Precision Medicine

Cardiovascular disease

International Journal of Molecular SciencesReview28 Sep

Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome

Lipid and ceramide metabolism

Research SquareHumansPreprint24 Sep

Molecular Circadian Disturbance in Human Blood Independently Predicts Multi-Disease Risk and Maps to Hepatic metabolism Pathways

American Journal of Kidney DiseasesHumans22 Sep

The Role of Angiopoietin-Like Proteins 3 and 4 and Their Target Lipases in CKD: A Drug-Target Mendelian Randomization Study

Current Opinion in LipidologyReview18 Sep

CRISPR therapy for dyslipidemia

Preprints.orgReviewPreprint8 Sep

Somatic Genome Editing in Cardiovascular Disease: Platforms, Targets, and Translational Progress

Cardiovascular disease

MetabolismHumans24 Aug

Discovery of functional variants regulating lipid metabolism in an East Asian population

Lipid and ceramide metabolism

AHA Scientific Sessions 2025 AbstractReview3 Nov

ANGPTL3 Targeting Monoclonal Antibodies Lead to Robust Reductions in LDL-C, Triglycerides, ApoB, and Non-HDL-C in Dyslipidemic Patients: A Meta-Analysis of 5 Randomized Controlled Trials

AHA Scientific Sessions 2025 AbstractHumans3 Nov

Characterization of Plasma Proteins Associated with Arterial Stiffness and Pressure Pulsatility

AHA Scientific Sessions 2025 AbstractHuman trial3 Nov

RNA INTERFERENCE OF ANGPTL3 VIA ZODASIRAN: A NEXT-GENERATION APPROACH FOR TREATING ATHEROGENIC DYSLIPIDEMIA